Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors

Expert Opinion on Drug Delivery

Volumn 10, Issue 12, 2013, Pages 1653-1668

  Molinaro, Roberto ^a,b   Wolfram, Joy ^b,c   Federico, Cinzia ^a   Cilurzo, Felisa ^a   Di Marzio, Luisa ^d   Ventura, Cinzia A ^e   Carafa, Maria ^f   Celia, Christian ^b,d   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chitosan; Gene therapy; Polyethylenimine; Polymeric vehicles; RNA interference; Small interfering RNA

Indexed keywords

BEVACIZUMAB; CARBON; CHITOSAN; CLATHRIN; CYCLODEXTRIN; DENDRIMER; DOUBLE STRANDED RNA; GOLD NANOPARTICLE; GRAPHENE OXIDE; HYDROXYL GROUP; IRON OXIDE; LIPOPLEX; MELITTIN; MESSENGER RNA; NANOMATERIAL; PACLITAXEL; PHTHALIC ANHYDRIDE; PLASMID DNA; POLYETHYLENEIMINE; POLYSTYRENE; REACTIVE OXYGEN METABOLITE; SALBUTAMOL; SHORT HAIRPIN RNA; SILVER NANOPARTICLE; SMALL INTERFERING RNA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; DRUG CARRIER;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; GENE ACTIVITY; GENE TARGETING; GLIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LENTIVIRINAE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RETICULOENDOTHELIAL SYSTEM; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY;

ANIMALS; CHITOSAN; DRUG CARRIERS; HUMANS; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84889017894     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.840286     Document Type: Review

References (130)

1. Cech TR, Bass BL. Biological catalysis by RNA. Annu Rev Biochem 1986;55:599-629 (Pubitemid 16070782)
2. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11 (Pubitemid 28099681)
3. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8 (Pubitemid 32494397)
4. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002;418(6893):38-9 (Pubitemid 34742563)
5. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12(5):329-40
6. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009;457(7228):426-33
7. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343-9 (Pubitemid 39265674)
8. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6(5):376-85 (Pubitemid 40637855)
9. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13(12):1097-101 (Pubitemid 44885920)
10. Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 2011;130(5):583-605
11. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9(2):102-14
12. Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development 2005;132(21):4645-52 (Pubitemid 41685275)
13. Lecellier CH, Dunoyer P, Arar K, et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005;308(5721):557-60 (Pubitemid 40570587)
14. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13(6):541-52
15. Okamura K, Ishizuka A, Siomi H, Siomi MC. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev 2004;18(14):1655-66 (Pubitemid 38938183)
16. Martinez J, Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes Dev 2004;18(9):975-80
17. Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003;278(45):44312-19 (Pubitemid 37377177)
18. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358(5):502-11 (Pubitemid 351185806)
19. Lu Z, Bast RC Jr. Tumor suppressor genes. Cancer Treat Res 2009;149:109-29
20. Tan FL, Yin JQ. Application of RNAi to cancer research and therapy. Front Biosci 2005;10:1946-60 (Pubitemid 40529046)
21. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102(16):5820-25 (Pubitemid 40559643)
22. Prasanthi JR, Larson T, Schommer J, Ghribi O. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus. PLoS ONE 2011;6(10):e26420
23. Sapru MK, Yates JW, Hogan S, et al. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 2006;198(2):382-90
24. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11(4):429-33 (Pubitemid 40562334)
25. Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006;1082:172-9 (Pubitemid 44955461)
26. He F, Chen EQ, Liu L, et al. Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA. Liver Int 2012;32(5):742-51
27. Czech MP, Aouadi M, Tesz GJ. RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 2011;7(8):473-84
28. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNAdelivery. J Control Release 2007;121(1-2):64-73 (Pubitemid 47126065)
29. Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012;19(6):367-73
30. Wang J, Lu Z, Wientjes MG, Au JLS. Delivery of siRNA Therapeutics: barriers and Carriers. AAPS J 2010;12(4):492-503
31. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-8 (Pubitemid 39545841)
32. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21(5):797-802
33. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci USA 2004;101(40):14385-9 (Pubitemid 39346758)
34. Weissmann G. Lysosomes. N Engl J Med 1965;273(21):1143-9
35. Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 2010;5(3):328-49
36. Kim SS, Garg H, Joshi A, Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009;15(11):491-500
37. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5(3):161-71 (Pubitemid 40314948)
38. Tao L, Hu W, Liu Y, et al. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med (Maywood) 2011;236(1):20-9
39. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11(3):263-70 (Pubitemid 40460553)
40. Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010;10(5):534-42
41. Jafari M, Chen P. Peptide mediated siRNA delivery. Curr Top Med Chem 2009;9(12):1088-97
42. Choi KM, Choi SH, Jeon H, et al. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano 2011;5(11):8690-9
43. Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 2006;12(1):1-3
44. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J 2009;11(4):639-52
45. Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 2009;26(3):657-66
46. Braun GB, Pallaoro A, Wu G, et al. Laser-Activated Gene Silencing via Gold Nanoshell siRNA Conjugates. ACS Nano 2009;3(7):2007-15
47. Biswal BK, Debata NB, Verma RS. Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate. Mol Biol Rep 2010;37(6):2919-26
48. Hwa Kim S, Hoon Jeong J, Chul Cho K, et al. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J Control Release 2005;104(1):223-32
49. Andon FT, Fadeel B. Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials. Acc Chem Res 2013;46(3):733-42
50. Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol 2012;9:20
51. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesiculartransport pathway to the ER. Nat Cell Biol 2001;3(5):473-83 (Pubitemid 32422083)
52. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004;84(4):1341-79 (Pubitemid 39287953)
53. Dauty E, Remy JS, Zuber G, Behr JP. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 2002;13(4):831-9 (Pubitemid 34801126)
54. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12(5):461-6 (Pubitemid 40394299)
55. Moriguchi R, Kogure K, Akita H, et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 2005;301(1-2):277-85 (Pubitemid 41206613)
56. Kim HS, Han HD, Armaiz-Pena GN, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011;17(7):1713-21
57. Monteagudo S, Perez-Martinez FC, Perez-Carrion MD, et al. Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine (Lond) 2012;7(4):493-506
58. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006;58(1):32-45
59. Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16(8):1273-9 (Pubitemid 29393618)
60. Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 2006;58(14):1523-31 (Pubitemid 44820504)
61. Arote R, Kim TH, Kim YK, et al. A biodegradable poly(ester amine)-based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 2007;28(4):735-44 (Pubitemid 44647450)
62. Kim YH, Park JH, Lee M, et al. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release 2005;103(1):209-19 (Pubitemid 40248573)
63. Mao S, Neu M, Germershaus O, et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 2006;17(5):1209-18 (Pubitemid 44455329)
64. Boussif O, Lezoualch F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
65. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17(7):751-66 (Pubitemid 44100720)
66. Hobel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12(3):287-300
67. Grayson AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006;23(8):1868-76 (Pubitemid 44200551)
68. Jeong GJ, Byun HM, Kim JM, et al. Biodistribution and tissue expression kinetics of plasmid DNA complexed with polyethylenimines of different molecular weight and structure. J Control Release 2007;118(1):118-25 (Pubitemid 46283104)
69. Goula D, Remy JS, Erbacher P, et al. Size, diffusibility and transfection performance of linear PEI/ DNA complexes in the mouse central nervous system. Gene Ther 1998;5(5):712-17 (Pubitemid 28256824)
70. Behr JP. The proton sponge: a trick to enter cells the viruses did not exploit. Chimia (Aarau) 1997;51(1-2):34-6
71. Harvey WR. Physiology of V-ATPases. J Exp Biol 1992;172:1-17
72. Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/ DNA complexes. J Control Release 2009;139(2):88-93
73. Yue Y, Jin F, Deng R, et al. Revisit complexation between. DNA and polyethylenimine-effect of length of free polycationic chains on gene transfection. J Control Release 2011;152(1):143-51
74. Allende D, Simon SA, McIntosh TJ. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys J 2005;88(3):1828-37 (Pubitemid 40976196)
75. Yang L, Harroun TA, Weiss TM, et al. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001;81(3):1475-85 (Pubitemid 32783588)
76. Ogris M, Carlisle RC, Bettinger T, Seymour LW. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 2001;276(50):47550-5
77. Høgset A, Prasmickaite L, Selbo PK, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004;56(1):95-115 (Pubitemid 38045426)
78. Ndoye A, Dolivet G, Høgset A, et al. Eradication of p53-mutated head and neck squamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization. Mol Ther 2006;13(6):1156-62 (Pubitemid 43796156)
79. Hobel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12(3):287-300
80. Hendruschk S, Wiedemuth R, Aigner A, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011;13(10):1074-89
81. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 2008;25(12):2972-82
82. Kawakami S, Ito Y, Charoensit P, et al. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther 2006;317(12):1382-90 (Pubitemid 43764145)
83. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000;11(18):2493-513
84. Tousignant JD, Zhao H, Yew NS, et al. DNA sequences in cationic lipid:pDNAmediated systemic toxicities. Hum Gene Ther 2003;14(3):203-14 (Pubitemid 36423440)
85. Song WJ, Du JZ, Sun TM, et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010;6(2):239-46
86. Zhang L, Lu Z, Zhao Q, et al. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small 2011;7(4):460-4
87. Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEIPEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine 2011;6:1661-73
88. Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8(2):137-43
89. Genetic Immunity. DermaVir Patch (LC002) in HIV-1 Infected Treatment-naive Patients. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 18]. Available from: http://clinicaltrials.gov/ show/NCT00711230 NLM Identifier: NCT00711230
90. BioCancell Therapeutics Israel Ltd. Phase 2b, Trial of Intravesical DTAH19/ PEI in Patients With Intermediate-Risk Superficial Bladder Cancer. Bethesda (MD): National Library of Medicine (US). 2000-. Available from: http://clinicaltrials.gov/ show/NCT00595088 NLM Identifier: NCT00595088 Cited October 18 2012
91. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5(4):387-91 (Pubitemid 29180575)
92. Kumar M, Behera AK, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002;13(12):1415-25
93. Dai H, Jiang X, Tan GC, et al. Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery. Int J Nanomedicine 2006;1(4):507-22
94. Jean M, Alameh M, Buschmann MD, Merzouki A. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther 2011;18(8):807-16
95. Pille JY, Li H, Blot E, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006;17(10):1019-26 (Pubitemid 46076743)
96. Howard KA, Paludan SR, Behlke MA, et al. Chitosan/ siRNA nanoparticle-mediated TNFalpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17(1):162-8
97. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nature Med 2005;11(9):944-51 (Pubitemid 41294439)
98. Luo Y, Zhai X, Ma C, et al. An inhalable beta 2-adrenoceptor liganddirected guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J Control Release 2012;162(1):28-36
99. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010;62(1):12-27
100. Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release 2012;161(2):496-504
101. Anthonsen MW, Smidsrod O. Hydrogen ion titration of chitosans with varying degrees of N-acetylation by monitoring induced 1H-NMR chemical shifts. Carbohydrate Polym 1995;26(4):303-5
102. Liu WG, De Yao K, Liu QG. Formation of a DNA/N-dodecylated chitosan complex and salt-induced gene delivery. J Appl Polym Sci 2001;82(14):3391-5 (Pubitemid 33046363)
103. Thanou M, Florea BI, Geldof M, et al. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials 2002;23(1):153-9 (Pubitemid 33041349)
104. Rojanarata T, Opanasopit P, Techaarpornkul S, et al. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res 2008;25(12):2807-14
105. Malmo J, Sorgard H, Varum KM, Strand SP. siRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. J Control Release 2011;158(2):261-8
106. Wei W, Lv PP, Chen XM, et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 2013;34(15):3912-23
107. Nawroth I, Alsner J, Behlke MA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFa prevents radiation-induced fibrosis. Radiother Oncol 2010;97(1):143-8
108. Shu XZ, Zhu KJ. The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur J Pharm Biopharm 2002;54(2):235-43 (Pubitemid 34919399)
109. Lee MK, Chun SK, Choi WJ, et al. The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer. Biomaterials 2005;26(14):2147-56
110. Boateng JS, Matthews KH, Stevens HN, Eccleston GM. Wound healing dressings and drug delivery systems: a review. J Pharm Sci 2008;97(8):2892-923
111. Lee J, Yun KS, Choi CS, et al. T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles. Bioconjug Chem 2012;23(6):1174-80
112. Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16(15):3910-22
113. Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005;101(1-3):151-62 (Pubitemid 39600979)
114. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004;83(3):97-111 (Pubitemid 38765217)
115. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011;63(3):152-60
116. Li W, Huang Z, MacKay JA, et al. Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med 2005;7(1):67-79
117. Moghimi SM, Andersen AJ, Hashemi SH, et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release 2010;146(2):175-81
118. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8 (Pubitemid 41483874)
119. Kievit FM, Veiseh O, Bhattarai N, et al. PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection. Adv Funct Mater 2009;19(14):2244-51
120. Jere D, Jiang HL, Kim YK, et al. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int J Pharm 2009;378(1-2):194-200
121. Ping Y, Liu C, Zhang Z, et al. Chitosangraft-( PEI- beta-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 2011;32(32):8328-41
122. Malhotra M, Lane C, Tomaro-Duchesneau C, et al. A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine 2011;6:485-94
123. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114(1):100-9 (Pubitemid 44128621)
124. Weber ND, Merkel OM, Kissel T, Munoz-Fernandez MA. PEGylated poly (ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J Control Release 2012;157(1):55-63
125. Huang Y, Lin D, Jiang Q, et al. Binary and ternary complexes based on polycaprolactonegraft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery. Biomaterials 2012;33(18):4653-64
126. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011;183(4):531-8
127. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005;12(5):900-9 (Pubitemid 41614486)
128. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522.e1-1522.e14
129. Shoshani T, Faerman A, Mett I. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22(7):2283-93 (Pubitemid 34224633)
130. Pechala's Reports. Tekmira Pharmaceuticals CP (TEKMIRA) 12 months forecast. 2013.